Treatment of MM: Upcoming Novel Therapies.

Treatment for myeloma has dramatically changed over the past decade, as has overall survival, due in large part to the development of new targeted agents. While proteasome inhibitors and immunomodulatory agents have contributed to improved outcomes, additional new options remain an unmet medical need. Classes of emerging agents include those targeting epigenetics, such as histone deacetylase inhibitors, monoclonal antibodies, and other emerging targets, such as kinesin spindle protein (KSP) inhibitors, cyclin dependent kinase (CDK) inhibitors, and nuclear protein export inhibitors. Future treatment approaches will need to identify how and when to incorporate these treatment options to optimally treat patients with relapsed or refractory myeloma.